Proprietary Cocrystal Program for PTSD, Cancer, IBD, Stroke, and Other Rare Diseases

Scientific and Clinical Validation

  • Cannabidiol (CBD) is known to exist in polymorphic states and has a low melting point, poor absorption and bioavailability (learn more about polymorphism)
  • CBD is a proven treatment for epilepsy and is used in a medicine to treat spasticity in Multiple Sclerosis (MS)
  • Strong preclinical and clinical evidence supports treatment with CBD in numerous anxiety disorders
  • Cocrystalization is a well-established, solid-state approach to improve physicochemical properties of pharmaceutical ingredients, including polymorphism, bioavailability, absorption, melting point, consistency and chemical stability
  • Numerous approved drugs are cocrystals
  • Strong preclinical evidence supports treatment with CBD in cancer
  • Ongoing pre-clinical studies in cancer and anxiety

Formulation and Intellectual Property

  • Proprietary cocrystal of canibidiol (CBD) and tetramethylpyrazine (TMP)
  • One patent issued in US
  • Three pending patent applications


  • PTSD
  • Cancer
  • IBD
  • Stroke
  • Rare Diseases